Abstract:O‐linked N ‐acetylglucosamine (O‐GlcNAc) is a highly dynamic post‐translational modification that involves an addition of a single N‐ acetylglucosamine to serine and threonine residue in mitochondria, nuclear and cytoplasmic proteins. O‐GlcNAc cycling is the addition and removal of O‐GlcNAc by O‐GlcNAc transferase (OGT) and O‐GlcNAcase (OGA) respectively. Disruptions in O‐GlcNAc cycling contribute to diseases such as diabetes, cancer, and neurodegeneration. Accumulative dysfunctional mitochondria can also lead to the development of neurodegenerative diseases, and importantly, O‐GlcNAcylation regulates mitochondrial function. Previously, using a proteomics based screen we found that altering the expression of OGT and OGA disrupted mitochondrial protein expression, including proteins involved in the respiratory chain and TCA cycle. Furthermore, mitochondrial morphology in the over‐expressing cells had reduced and disorganized cristae and altered shape and size. Both cellular respiration and glycolysis was impaired in the OGT/OGA gain of function cells. These data suggested that O‐GlcNAc cycling was essential for the proper regulation of mitochondrial function. We hypothesized that prolonged elevations in cellular O‐GlcNAc levels would alter the metabolic profile of the cell. We disrupted O‐GlcNAc cycling by either treating SH‐SY5Y neuroblastoma cells with low levels of Glucosamine (GlcN) or OGA inhibitor Thiamet‐G (TMG). Importantly, the metabolic substrate for O‐GlcNAcylation is UDP‐GlcNAc. UDP‐GlcNAc is synthesized via the hexosamine biosynthetic pathway, which is highly sensitive towards the availability of nutrients in the cellular environment. GlcN feeds into the hexosamine biosynthetic pathway after the first rate‐limiting enzyme GFAT1, glutamine fructose‐6‐phosphate aminotransferase 1, and additional supplementation of GlcN increases O‐GlcNAcylation via elevating the synthesis of UDP‐GlcNAc. We found that prolonged TMG/GlcN treatment improved mitochondrial function. In the TMG/GlcN treated cells, reactive oxygen species (ROS) production was significantly reduced. Interestingly, the protein expression of the mitochondrial antioxidant, manganese superoxide dismustase (MnSOD) was lower. Additionally, ATP production was lower in these TMG/GlcN treated cells. Furthermore, we found that mitochondrial were longer in shape and mitochondrial fusion/fission protein expressions were decreased. Altogether, these data demonstrated that prolonged alterations to the cellular homeostasis of O‐GlcNAc levels improve mitochondrial function likely through reprogramming of metabolic transcriptional programs. Further understanding of how O‐GlcNAc cycling regulates metabolism will provide new insights into metabolic diseases such as cancer and Alzheimer's. Support or Funding Information RO1DK100595

Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis

O-GlcNAcylation of Core Components of the Translation Initiation Machinery Regulates Protein Synthesis.

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling

Spatiotemporal Activation of Protein O-GlcNAcylation in Living Cells.

O-GlcNAcylation, a Sweet Link to the Pathology of Diseases

Regulation of cancer metabolism by O-GlcNAcylation

Transcriptional Regulation of O-GlcNAc Homeostasis is Disrupted in Pancreatic Cancer

Protein O-GlcNAcylation: emerging mechanisms and functions

O‐GlcNAcylation: cellular physiology and therapeutic target for human diseases

Hepatocyte nuclear factor 1 alpha (HNF1A) regulates transcription of O-GlcNAc transferase in a negative feedback mechanism.

O-GlcNAcylation in cancer development and immunotherapy

A Conserved Splicing Silencer Dynamically Regulates O-GlcNAc Transferase Intron Retention and O-GlcNAc Homeostasis

Regulation and Clinical Significance of O-GlcNAc Transferase in Cancer

O-GlcNAcylation is a Novel Regulator of Lung and Colon Cancer Malignancy

New Insights Into the Biology of Protein O-GlcNAcylation: Approaches and Observations

O‐GlcNAcylation Promotes the Migratory Ability of Hepatocellular Carcinoma Cells Via Regulating FOXA2 Stability and Transcriptional Activity

O-GlcNAcylation: an Important Post-Translational Modification and a Potential Therapeutic Target for Cancer Therapy

Extracellular arginine availability modulates eIF2α O-GlcNAcylation and heme oxygenase 1 translation for cellular homeostasis

Elevated O‐GlcNAcylation levels improve mitochondrial function

O‐GlcNAc transferase activates stem‐like cell potential in hepatocarcinoma through O‐GlcNAcylation of eukaryotic initiation factor 4E

Cryo-EM structure of human O-GlcNAcylation enzyme pair OGT-OGA complex